1. Home
  2. Labeler Index
  3. Aphena Pharma Solutions - Tennessee, Llc
  4. 71610-800
  5. Product Images: Pregabalin

Product Images Pregabalin

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Label - 71610 0800 30
  2. Aphena - Aphena
  3. Figure 1 - pregabalin fig01
  4. Figure 2 - pregabalin fig02
  5. Figure 3 - pregabalin fig03
  6. Figure 4 - pregabalin fig04
  7. Figure 5 - pregabalin fig05
  8. Figure 6 - pregabalin fig06
  9. Figure 7 - pregabalin fig07
  10. Figure 9 - pregabalin fig08
  11. Figure 10 - pregabalin fig09
  12. Figure 11 - pregabalin fig10
  13. Figure 12 - pregabalin fig11
  14. Figure 13 - pregabalin fig13
  15. Cockcroft and Gault equation - pregabalin formula
  16. Chemical Structure - pregabalin str

Product Label Images

The following 16 images provide visual information about the product associated with Pregabalin NDC 71610-800 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 71610 0800 30

Label - 71610 0800 30

This is not readable.*

Aphena - Aphena

Aphena - Aphena

Figure 1 - pregabalin fig01

Figure 1 - pregabalin fig01

Figure 2 - pregabalin fig02

Figure 2 - pregabalin fig02

Figure 3 - pregabalin fig03

Figure 3 - pregabalin fig03

Figure 4 - pregabalin fig04

Figure 4 - pregabalin fig04

This description is not available.*

Figure 5 - pregabalin fig05

Figure 5 - pregabalin fig05

This text provides information on different medication doses given to patients (Fregabalin 100 mg, Pregataiin 80 mg, Placebo) and the improvement levels of these patients. It also includes a numerical representation showing the percentage of patients improved and the percentage of improvement in pain from the baseline.*

Figure 6 - pregabalin fig06

Figure 6 - pregabalin fig06

This text provides information about a study comparing the effects of different dosages of a certain medication with a placebo. The dosages evaluated are 50mg/day, 150mg/day, 300mg/day, and 600mg/day. It mentions that there is a statistically significant difference compared to the placebo group.*

Figure 7 - pregabalin fig07

Figure 7 - pregabalin fig07

Figure 9 - pregabalin fig08

Figure 9 - pregabalin fig08

This text provides data on the percentage of patients improved with different doses of pregabalin (300mg and 450mg daily) compared to a placebo. It also includes a graph showing the percent improvement in pain from baseline. The graph's x-axis ranges from 210 to 280, while the y-axis shows the percent of patients improved, ranging from 0 to 100.*

Figure 10 - pregabalin fig09

Figure 10 - pregabalin fig09

Figure 11 - pregabalin fig10

Figure 11 - pregabalin fig10

Figure 12 - pregabalin fig11

Figure 12 - pregabalin fig11

Figure 13 - pregabalin fig13

Figure 13 - pregabalin fig13

The provided text contains information on responder rates of different treatment groups. It includes percentages such as 40.6%, 29.1%, and 22.6%. The comparison seems to involve a placebo and different dosage levels of a substance. The document also mentions values like 93, 103, and 9%.*

Cockcroft and Gault equation - pregabalin formula

Cockcroft and Gault equation - pregabalin formula

This formula calculates the Creatinine Clearance (CLCT) based on the age and weight of the patient for males, and for females, the result is multiplied by 0.85. The formula also involves the serum creatinine level in mg/dL.*

Chemical Structure - pregabalin str

Chemical Structure - pregabalin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.